[Double-blind comparative study of Bi-Profenid tablets and Profenid capsules in inflammatory rheumatism].
The effectiveness of Bi-Profenid tablets and Profenid capsules was studied comparatively in patients with inflammatory joint disease. 43 patients with rheumatoid arthritis or various chronic inflammatory joint diseases were given 300 mg of Bi-Profenid in 2 daily oral doses and 300 mg of Profenid in 3 daily oral doses, for two consecutive 7 day periods. This double blind cross-over study was carried out in two rheumatology centers. Effectiveness of the two forms of ketoprofen on morning stiffness and pain scale was found to be comparable. However, patients more often preferred Bi-Profenid (15 cases) to Profenid (10 cases); 12 patients reported no difference. Tolerance was excellent in 92.7% of cases under Profenid capsules and in 94.8% of cases under Bi-Profenid tablets.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002214:Capsules; D002648:Child; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010666:Phenylpropionates / Q000008:administration & dosage*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013607:Tablets
D002214:Capsules; D003692:Delayed-Action Preparations; D010666:Phenylpropionates; D013607:Tablets; D007660:Ketoprofen
Etude comparative à double insu du Bi-Profénid comprimés et du Profénid gélules dans les rhumatismes inflammatoires.